Antiproliferative coated stents and intracoronary brachytherapy: Common traits and differences;Antiproliferativ beschichtete stents und intrakoronare brachytherapie: Gemeinsamkeiten und unterschiede

Zeitschrift fur Kardiologie

Volumn 91, Issue 6, 2002, Pages 443-457

  Silber, S ^a  

^a Kardiologische Praxis in der Klinik   (Germany)

Author keywords

Antiproliferative coated stents; Brachytherapy; PTCA; Restenosis

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; BIOMATERIAL; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; TICLOPIDINE;

BLOOD VESSEL DIAMETER; BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFECT; HUMAN; METHODOLOGY; RADIATION DOSE; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME; ANGIOCARDIOGRAPHY; CELL DIVISION; COMPARATIVE STUDY; RADIATION EXPOSURE; RADIOGRAPHY; THROMBOCYTE AGGREGATION;

BRACHYTHERAPY; CELL DIVISION; CLINICAL TRIALS; COATED MATERIALS, BIOCOMPATIBLE; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; ENGLISH ABSTRACT; HUMAN; PLATELET AGGREGATION; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME; HUMANS;

EID: 0036018260     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-002-0817-z     Document Type: Review

References (95)

1. Cutting balloon angioplasty for the treatment of in-stent restenosis: A matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty
2. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
3. Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia
4. The sirolimus coated stent: Will the Achilles heel of interventional cardiology finally be cured?
5. Five year clinical and angiographic follow-up after intracoronary 192-iridium radiation therapy
6. Long-term angiographic and clinical out-come after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans
7. Arterial paclitaxel distribution and deposition
8. Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials
9. Treatment of in-stent restenosis using paclitaxel eluting stents: A single centre pilot trial
10. Positionspapier zur intrakoronaren brachytherapie. Stellungnahme der Deutschen gesellschaft für kardiologie - Herz und kreislaufforschung, bearbeitet im auftrag der kommission für klinische kardiologie
11. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months
12. Gold-coated NIR stents in porcine coronary arteries
13. Treatment of in-stent-restenosis by combining cutting balloon angioplasty and vascular brachytherapy: A report from the RENO registry
14. Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (EvaLUation of pacliTaxel Eluting Stent) clinical trial
15. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels
16. SCORE 6 mo angiographic results: Improved restenosis in patients receiving the QUADDS-QP2 drug-eluting stent compared with the control, bare stents
17. Inhibition of in-stent restenosis by the quanam drug eluting polymer stent; two year follow-up
18. SCORE trial interim safety results: Despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent
19. TAXUS I: Prospective, randomized, double-blind comparison of NIRx TM stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls
20. Stent coatings and local drug delivery
21. The STING study final results
22. A multicenter, randomized trial comparing silicon carbide coated stents with stainless steel stents in acute coronary syndrome (TRUST Study)
23. Increased apoptotic cell death in the neointima after stent-based vascular irradiation: Role of radiation-induced apoptosis for restenosis reduction
24. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis
25. Late stent thrombosis in the absence of prior intracoronary brachytherapy
26. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo
27. Antiproliferative stent coatings: Taxol and related compounds
28. The incidence of late stent thrombosis without the use of brachytherapy
29. Stent design related neointimal tissue proliferation in human coronary arteries
30. Coronary in-stent restenosis predictors, treatment and prevention
31. Intracoronary β-irradiation with liquid rhenium-188 to prevent restenosis following angioplasty of de-novo and restenotic lesions results from the randomized ECRIS II trial
32. Novel drug-delivery stent. Intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system
33. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch
34. Will there always be an edge to radiation for the prevention of restenosis?
35. Late stent thrombosis without antecedent brachytherapy: Confirmation and treatment with rheolytic thrombectomy
36. Increased risk of restenosis after placement of gold-coated stents. Results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease
37. Predictive factors of restenosis after coronary stent placement
38. QP2
39. The edge effect: The impact of vessel injury and dose fall-off after treatment of in-stent restenosis with Sr-90 radiation. Results from the start trial
40. Effects of the QUADDS-QP2 drug-eluting stent extend beyond the targeted area into adjacent non-stented zones: Results of the SCORE trial
41. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting
42. Beta versus gamma for catheter-based intravascular brachytherapy: Dosimetric perspectives in the presence of metallic stents and calcified plaques
43. Late acute thrombosis after paclitaxel eluting stent implantation
44. Radiation and late thrombosis: Issues, facts, and solutions
45. 17. Bericht tiber die leistungszahlen der Herzkatheterlabore in der Bundesrepublik Deutschland
46. Standalone cutting balloon angioplasty for the treatment of stent-related restenosis: Acute results and 3- to 6-month angiographic recurrent restenosis rates
47. A monk's prayer: O Lord what is the answer to in-stent restenosis? Commentary on the TRAPIST study
48. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT-trial
49. Inhibition of restenosis with extra-emitting radiotherapy; Report of the Proliferation Reduction with Vascular Energy Trail (PREVENT)
50. SCRIPPS II: A pilot trial of localized radiation therapy (brachytherapy) to inhibit restenosis after stenting
51. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasonic follow-up
52. Paclitaxel release from inert polymer material-coated stents curtails coronary in-stent restenosis in pigs
53. Paclitaxel (Taxol)
54. The Molecular and cellular biologic basis for the radiation treatment of benign proliferative diseases
55. Promotion of microtubule assembly in vitro by Taxol
56. Decreased rate of coronary restenosis after lowering of plasma homocystein levels
57. The TRAPIST study. A multicentre randomised placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
58. I Like the candy. I hate the wrapper. The 32P radioactive stent
59. The RAVEL study: A randomized study with the sirolimus coated Bx velocity balloon-expandable stent in the treatment of patients with de-novo native coronary artery lesions
60. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries
61. Improved outcome with longer radiation sources: Final results of the RENO registry in 1098 patients
62. Notwendigkeit für die einjährige gabe von clopidogrel zur vermeidung später stentthrombosen nach intrakoronarer brachytherapie: Erste ergebnisse des Deutschen IST-Registers
63. Für die START-studienteilnehmer: Die START-studie
64. The quanam QUADDS-QP2 stent
65. The Boston Scientific antiproliferative, Paclitaxel during stents (TAXUS)
66. Prevention of nickle release does not prevent instent restenosis
67. Kombinierte anwendung von brachytherapie und cutting-balloon zur therapie rezidivierender in-stent-restenosen
68. Verbesserung des ergebnisses einer intrakoronaren strahlentherapie bei in-stent-restenose durch längere strahlenquellen bei gleicher läsionslänge: Vergleich von START-30 mit START-40
69. The NUGGET trial (NIR Ultimate Gold-Gilded Equivalency Trial): 6 Months post-procedure safety and efficacy results
70. Beeinflußt die strebendicke das ausmaß der in-stent restenose?
71. Die lernkurve bei intrakoronarer brachytherapie und ihr einfluß auf das angiographische 6 monatsergebnis: Endgültige ergebnisse der Europäischen BRIE (Beta Radiation In Europe)-studie
72. Intrakoronare brachytherapie mit strontium/yttrium-90
73. Sicherheit und durchführbarkeit der intrakoronaren brachytherapie mit dem novoste-system im rahmen von internationalen multicenter-studien
74. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat
75. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries
76. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up
77. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
78. Catheter-based radiotherapy to inhibit restenosis after coronary stenting
79. Three-year clinical and angiographic follow-up after intracoronary radiotherapy. Results of a randomized clinical trial
80. Living the dream of no restenosis
81. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries
82. "Edge effect" of 32P radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff
83. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty
84. Feasibility of intracoronary β-irradiation to reduce restenosis after balloon angioplasty. A clinical pilot study
85. Predictors of recurrent in-stent restenosis following mechanical treatment by angioplasty or rotational atherectomy: Results from an angiographically controlled prospective trial (ARTIST study)
86. Twelve versus six months of clopidogrel to prevent late total occlusion after gamma radiation therapy for in-stent restenosis: WRIST 12 vs WRIST PLUS
87. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary γ-radiation in patients with in-stent restenosis. Washington radiation for in-stent restenosis trial plus 6 months of clopidogrel (WRIST PLUS)
88. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis
89. High dose intracoronary gamma radiation for patients with diffuse in-stent restenosis
90. Beta radiation to inhibit recurrence of in-stent restenosis: Study design. Device and dosimetry details of the Multicenter Randomized Double Blind study
91. Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
92. Paclitaxel and cell division